Cost-effectiveness of Ezetimibe plus statin lipid-lowering therapy: A systematic review and meta-analysis of cost-utility studies
Open Access
- 16 June 2022
- journal article
- review article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 17 (6) , e0264563
Abstract
In addition to statin therapy, Ezetimibe, a non-statin lipid-modifying agent, is increasingly used to reduce low-density lipoprotein cholesterol and atherosclerotic cardiovascular disease risk. Literature suggests the clinical effectiveness of Ezetimibe plus statin (EPS) therapy; however, primary evidence on its economic effectiveness is inconsistent. Hence, we pooled incremental net benefit to synthesise the cost-effectiveness of EPS therapy. We identified economic evaluation studies reporting outcomes of EPS therapy compared with other lipid-lowering therapeutic agents or placebo by searching PubMed, Embase, Scopus, and Tufts Cost-Effective Analysis registry. Using random-effects meta-analysis, we pooled Incremental Net Benefit (INB) in the US $ with a 95% confidence interval (CI). We used the modified economic evaluations bias checklist and GRADE quality assessment for quality appraisal. The pooled INB from twenty-one eligible studies showed that EPS therapy was significantly cost-effective compared to other lipid-lowering therapeutic agents or placebo. The pooled INB (95% CI) was $4,274 (621 to 7,927), but there was considerable heterogeneity (I2 = 84.21). On subgroup analysis EPS therapy is significantly cost-effective in high-income countries [$4,356 (621 to 8,092)], for primary prevention [$4,814 (2,523 to 7,106)], and for payers’ perspective [$3,255 (571 to 5,939)], and from lifetime horizon [$4,571 (746 to 8,395)]. EPS therapy is cost-effective compared to other lipid-lowering therapeutic agents or placebo in high-income countries and for primary prevention. However, there is a dearth of evidence from lower-middle-income countries and the societal perspective.Keywords
All Related Versions
Funding Information
- Department of Health Research ((T.11011/08/2017-HR(Part-1)/E-office -8025571)
This publication has 67 references indexed in Scilit:
- Concordance between administrative claims and registry data for identifying metastasis to the bone: an exploratory analysis in prostate cancerBMC Medical Research Methodology, 2014
- Effect of Long-Term Exposure to Lower Low-Density Lipoprotein Cholesterol Beginning Early in Life on the Risk of Coronary Heart DiseaseJACC, 2012
- GRADE guidelines: 1. Introduction—GRADE evidence profiles and summary of findings tablesJournal of Clinical Epidemiology, 2011
- Economic evaluation of ezetimibe combined with simvastatin for the treatment of primary hypercholesterolaemiaNetherlands Heart Journal, 2011
- Projected Cost-Effectiveness of Ezetimibe/Simvastatin Compared with Doubling the Statin Dose in the United Kingdom: Findings from the INFORCE StudyValue in Health, 2010
- Population-based health-economic evaluation of the secondary prevention of coronary heart disease in FinlandCurrent Medical Research and Opinion, 2009
- The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trialsBMJ, 2009
- Estimating the health benefits and costs associated with ezetimibe coadministered with statin therapy compared with higher dose statin monotherapy in patients with established cardiovascular disease: Results of a Markov model for UK costs using data registriesClinical Therapeutics, 2008
- Statin-related adverse events: A meta-analysisClinical Therapeutics, 2006
- Inhibition of Intestinal Cholesterol Absorption by Ezetimibe in HumansCirculation, 2002